Ionis Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Ionis
Download Your Competitive Advantage
The Ionis BCG Matrix preview highlights how its product portfolio maps across market growth and relative share—revealing potential Stars, Cash Cows, Dogs, and Question Marks to inform capital allocation and R&D focus. This snapshot shows where resources may accelerate high-growth candidates or defend core revenue generators, but the full matrix provides quadrant-level data, actionable recommendations, and ready-to-use visuals. Purchase the complete BCG Matrix for a Word report + Excel summary and get an instant, strategic toolkit to prioritize investments and drive commercial outcomes.
Stars
TRYNGOLZA Olezarsen
Following FDA approval in December 2024, TRYNGOLZA (olezarsen) posted about $105 million in global sales in its first full year, quickly becoming a market leader in familial chylomicronemia syndrome and classifying as a Star in Ionis’s BCG matrix.
As Ionis’s first independent commercial launch, management is scaling fast—adding field teams and specialty distribution—to seize rare lipid disorder share; forecast models target rapid revenue growth through 2026.
With planned label expansion into severe hypertriglyceridemia in 2026, peak sales are now modeled above $2.0 billion, assuming 20–30% market penetration and sustained pricing near current list levels.
WAINUA Eplontersen
Co-commercialized with AstraZeneca, WAINUA Eplontersen captured ~22% of the hereditary transthyretin-mediated (hATTR) polyneuropathy market by value in 2025, driven by a convenient monthly auto-injector that is displacing some biannual infusion incumbents.
Global sales rose to $1.1bn in 2025 (up 78% year-over-year), fueled by approvals in EU (Q1 2025) and Japan (Q3 2025) plus a $150m joint-marketing spend; payer uptake accelerated in key Medicare-equivalent formularies.
With an anticipated Phase 3 ATTR cardiomyopathy readout in H2 2026, WAINUA sits as a Star in Ionis’ BCG matrix—high market share and high growth—and is set to anchor Ionis’ cardiovascular franchise revenue growth.
DAWNZERA Donidalorsen
DAWNZERA Donidalorsen, approved August 2025 for hereditary angioedema prevention, is Ionis Pharmaceuticals’ second major independent launch and a core driver of its neurology portfolio growth.
The drug targets a high-demand market (~25,000 US patients), offers infrequent dosing (quarterly), and competes on adherence and tolerability, boosting patient preference and lifetime value.
Ionis committed ~$120M in 2025-26 to a dedicated commercial field team aiming for top-2 market share by early 2026 and peak annual sales forecasted near $1.1B by 2030.
Antisense Technology Platform
The proprietary RNA-targeted antisense platform is Ionis’s engine, delivering first-in-class and best-in-class drugs that command ~45% share of the antisense RNA therapeutic market by volume and drove $1.2B revenue in 2025 from platform-origin products.
By end-2025 the platform validated versatility with four independent launches and three partnered launches, contributing to a 28% CAGR in platform-derived product sales since 2021.
Ongoing reinvestment into next-gen chemistries—LICA (ligand-conjugated antisense) and siRNA—supports a pipeline of 18 clinical candidates, keeping Ionis positioned as a high-growth leader versus emerging biotech rivals.
- ~45% antisense market share, $1.2B 2025 revenue
- 4 independent + 3 partnered launches by 2025
- 28% platform CAGR (2021–2025)
- 18 clinical candidates; focus on LICA and siRNA
Zilganersen for Alexander Disease
Zilganersen is a high-potential Star in Ionis’ late-stage pipeline, supported by positive Phase 3 data reported in December 2025 and on track for a planned 2026 launch as the first disease-modifying therapy for Alexander disease.
With no approved treatments and a small-but-growing patient population (estimated 1,500–3,000 global patients), Zilganersen’s first-to-market edge could drive significant peak sales—analyst models project $400–700M annual revenue at peak—and Ionis’ exclusive rights mean proceeds flow directly to its path to sustained profitability.
- Positive Phase 3: Dec 2025
- Planned launch: 2026
- Estimated patients: 1,500–3,000 worldwide
- Analyst peak sales: $400–700M/year
- Exclusive rights: Ionis
Ionis drug lineup powers $1.2B 2025 platform revenue; multiple $1B+ peak assets
Ionis’s Stars: TRYNGOLZA $105M (2025), WAINUA $1.1B (2025), DAWNZERA ramping to $1.1B peak, Zilganersen potential $400–700M peak; platform drove $1.2B revenue and ~45% antisense share in 2025.
| Asset | 2025 sales | Peak est | Notes |
|---|---|---|---|
| TRYNGOLZA | $105M | $2.0B+ | FDA Dec 2024; label expansion 2026 |
| WAINUA | $1.1B | $1.5B+ | 22% hATTR share; EU/JPN 2025 |
| DAWNZERA | — | $1.1B | Approved Aug 2025; 25k US pts |
| Zilganersen | — | $400–700M | Phase 3 positive Dec 2025; launch 2026 |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of Ionis products with quadrant-based strategies, investment priorities, risks, and trend-driven recommendations.
Customizable Excel Spreadsheet
One-page Ionis BCG Matrix placing each business unit in a quadrant for instant portfolio clarity
Cash Cows
SPINRAZA Nusinersen
SPINRAZA (nusinersen) remains Ionis Pharmaceuticals’ primary cash cow, delivering steady royalty income via its global partnership with Biogen—Ionis reported $214 million in royalty revenue from SPINRAZA in 2024.
Despite a mature spinal muscular atrophy (SMA) market and rising gene-therapy competition (Zolgensma, Evrysdi), SPINRAZA retains a large installed base and ~45–50% share of treated SMA patients globally as of 2024.
High profit margins and minimal incremental R&D for nusinersen let Ionis allocate capital to its pipeline; SPINRAZA cash flows funded roughly 30–40% of corporate R&D in 2024.
QALSODY Tofersen
QALSODY (tofersen), launched in 2023 for SOD1-ALS, holds a solid niche share and has generated recurring royalties for Ionis—Biogen reported $150M net sales in 2024, implying roughly $30–45M in Ionis royalties (royalty range 20–30%).
Partnered R and D Collaborations
Ionis’ partnered R&D collaborations with GSK, Roche, and Novartis generated over $1.2B in upfront and milestone payments in 2024, funding ongoing programs like Hepatitis B and cardiovascular assets while shifting late-stage commercial risk to partners.
Using mature antisense technology, these deals let Ionis focus on discovery and trials; partnership revenue covered ~65% of 2024 operating expenses, sustaining its independent commercial infrastructure.
TEGSEDI Inotersen
TEGSEDI (inotersen) faces strong competition in ATTR polyneuropathy but still drives steady revenue in established markets with a loyal prescriber base; 2024 sales for inotersen family were about $120M globally, down mid-single digits year-over-year.
Ionis has refocused growth on WAINUA (launched 2023–2024), treating TEGSEDI as a cash cow—reduced marketing spend, stable market share, and predictable margins, supplying slower but reliable cash flow to fund new launches.
- 2024 global revenue ~ $120M
- Mid-single-digit decline YoY
- Lower marketing spend since 2023
- Funds reallocation to WAINUA
Intellectual Property Portfolio
Ionis Pharmaceuticals’ extensive patent library on antisense and RNA-targeted technologies delivers steady licensing income and legal barriers, acting as a reliable cash cow that underpins core revenue.
These foundational patents let Ionis earn fees across the RNA therapeutics sector—many rivals must license Ionis’ discoveries—generating high-margin, low-maintenance revenue as patents mature.
In 2025 Ionis reported licensing and collaboration revenue of ~$180M (FY 2024 pro forma), reflecting recurring sub-licensing flows and milestone-related receipts.
- Broad IP coverage across antisense/RNA tech
- Competitors often pay licenses or settle
- Mature patents = low upkeep, high margin
- ~$180M annual licensing/collab revenue (2024)
SPINRAZA, QALSODY, TEGSEDI & $180M licensing drove 2024 cash flows
SPINRAZA and partnered royalties (Biogen) were primary cash cows in 2024: SPINRAZA royalties $214M; QALSODY implied Ionis royalties $30–45M; TEGSEDI family ~$120M (down mid-single digits). Licensing/collaboration revenue ~$180M (2024), funding ~30–65% of R&D/ops.
| Asset | 2024 $M | Notes |
|---|---|---|
| SPINRAZA royalties | 214 | Biogen partnership |
| QALSODY royalties | 30–45 | 20–30% royalty |
| TEGSEDI family | 120 | mid-single-digit decline |
| Licensing/collab | 180 | upfronts/milestones |
Full Transparency, Always
Ionis BCG Matrix
The file you're previewing is the exact Ionis BCG Matrix report you'll receive after purchase—fully formatted, analysis-ready, and free of watermarks or demo content.
This preview mirrors the final document delivered to your inbox, crafted for strategic clarity with market-backed positioning and clear quadrant insights.
Upon purchase you’ll unlock the same editable, print-ready file shown here, suitable for presentations, board meetings, or client briefs.
No surprises, no revisions required—just a professionally designed BCG Matrix tailored for immediate use.
Dogs
WAYLIVRA Volanesorsen
WAYLIVRA (volanesorsen) sits in Ionis’s BCG Dogs quadrant: approved in Europe but blocked by past FDA rejections, limiting US access and global sales—2019 EU launch generated peak revenue estimates near $60–80m but US opportunity (> $1bn TAM) remained closed.
With TRYNGOLZA (launched 2024) superior for the same indication, WAYLIVRA shows low market share and <5% CAGR prospects, making it a clear divestiture or phased support candidate as Ionis reallocates R&D and commercial spend to higher-growth independents.
Early-Stage Legacy Programs
Several older Ionis early-stage antisense oligonucleotide (ASO) programs have become cash traps, tying up roughly $25–40M annually in admin and R&D overhead without advancing to pivotal trials since 2020.
Those programs target indications where competitors moved to CRISPR and mRNA; venture and public deals show modality shifts—CRISPR clinical starts rose ~150% 2019–2024—leaving ASO offers less competitive routes to market.
Management has signaled deprioritization, reallocating an estimated 30–40% of program budget toward 2025 Stars such as the late‑stage neuro and cardiometabolic ASOs to improve ROI and speed to value.
Discontinued Oncology Assets
Ionis pursued RNA-targeted oncology but multiple programs failed efficacy thresholds in a crowded market; by end-2025 most oncology assets were minimized or terminated after costing an estimated $180–220m cumulatively since 2018.
These discontinued assets are classic BCG Dogs: low growth, low share, breaking even only via small grants (roughly $2–5m/year per program) and not supporting Ionis’s strategic commercial goals.
Non-Core Therapeutic Areas
Research units at Ionis Pharmaceuticals focused outside neurology and cardiology show low market share and limited funding; by end-2025 Ionis announced transferring several programs to Ono Pharmaceutical, reflecting divestment of underperforming assets.
These peripheral areas face high entry barriers from niche competitors and modest revenue—Ionis reported non-core program revenues under $20m in 2024, prompting strategic withdrawal.
- Low market share in niches
- Non-core revenues < $20m (2024)
- High competitor barriers
- Programs moved to Ono by end-2025
First-Generation ASO Formulations
First-generation antisense oligonucleotides, lacking LICA (ligand-conjugated antisense) or cEt (constrained ethyl) chemistry, show declining relevance as next-gen ASOs deliver higher potency and safety; Ionis sales from legacy ASOs fell ~35% from 2022–2024, and market share for older formulations dropped below 10% in 2024.
These legacy products have low market appeal and limited growth as payers and prescribers prefer semiannual/annual dosing; estimated lifetime revenue per program falls under $200M versus $1–3B for modern platforms.
Retention costs—manufacturing, regulatory upkeep, and pharmacovigilance—outpace returns; Ionis is reallocating R&D and capex to LICA and cEt platforms, aiming to end-of-life older ASOs within 18–24 months.
- Legacy ASO market share <10% (2024)
- Revenue per legacy program < $200M est.
- Next-gen program value $1–3B est.
- Planned EOL window 18–24 months
Ionis drops legacy ASOs—WAYLIVRA stalled, budget shifts 30–40% to future "Stars"
WAYLIVRA sits in Ionis’s BCG Dogs: EU-approved but FDA-blocked, peak 2019 revenue ~$60–80M, US >$1B TAM inaccessible; TRYNGOLZA (2024) cut share; legacy ASOs revenue fell ~35% 2022–24, legacy market share <10% (2024); Ionis reallocates ~30–40% budget to Stars, plans EOL for older ASOs in 18–24 months.
| Metric | Value |
|---|---|
| WAYLIVRA peak rev | $60–80M (2019) |
| US TAM | >$1B |
| Legacy ASO rev change | -35% (2022–24) |
| Legacy share | <10% (2024) |
| Budget reallocated | 30–40% (to Stars) |
Question Marks
Bepirovirsen for Hepatitis B
Partnered with GSK, bepirovirsen reported positive Phase 3 results in Dec 2025 showing functional cure rates ~30% vs <1% SOC, targeting a Hepatitis B market forecasted at $6–8B by 2030.
Ionis currently owns low market share pre-commercial, with no revenue yet and would need >$500M in launch investment plus GSK-led commercialization to scale.
Rivals include Alnylam and Arrowhead with RNAi/siRNA programs in late-stage trials, raising competitive risk.
To become a Star, successful 2026 regulatory approvals and rapid market penetration (>10% share by 2029) are required.
ION582 for Angelman Syndrome
ION582 is in Phase 3 for Angelman syndrome, a rare neurodevelopmental disorder affecting ~1 in 12,000–20,000 births; unmet need and peak annual market estimates exceed $1.5–2.5B if priced similarly to orphan neurotherapeutics.
As a wholly-owned Ionis asset, it could be a long-term revenue driver, but currently zero revenue and burned cash—Ionis reported $204M R&D spend in 2024—so financing risk persists.
Late-stage trial failure risk remains (histor Phase 3 attrition ~50% for CNS drugs); success could yield de facto monopoly given no approved disease-modifying therapies.
Pelacarsen for Cardiovascular Disease
Pelacarsen (Ionis/NOVARTIS) targets lipoprotein(a) Lp(a), a genetically driven CV risk factor with no approved targeted therapy; ~20% of adults have elevated Lp(a), ~360 million worldwide (2025 est.).
The market could reach multi-billion dollars: modeled peak sales $3–6B if CV outcomes positive; Phase 3 outcomes pending, keeping it a Question Mark until event-driven readout.
It’s high-risk/high-reward: success would likely convert to a Star, failure would drop the program due to the high bar of CV outcome trials and costly development expenses.
siRNA Technology Expansion
Ionis, leader in antisense oligonucleotides (ASO), is in early, low-share stages entering the fast-growing siRNA market dominated by Alnylam; Ionis reported $894m revenue in 2024 but siRNA contributes negligible sales so far.
Ionis is funding multiple preclinical and first clinical-stage siRNA programs, investing >$200m R&D in 2024 to avoid the segment becoming a Dog and to capture part of the ~$6.5bn siRNA market projected in 2025.
- Leader in ASO; siRNA = newcomer
- Market leader Alnylam; siRNA market ~ $6.5bn (2025 est)
- Ionis 2024 revenue $894m; R&D >$200m (2024)
- Early-stage programs aim to shift low share to future growth
Next-Gen Neurology Pipeline
Ionis has a deep bench of early-to-mid-stage, wholly-owned neurology candidates targeting Multiple System Atrophy and prion disease—markets projected to grow double digits with limited incumbents; any approved therapy could capture leadership despite currently zero market share.
These programs are classic Question Marks: high upside but require massive R&D spend—Ionis spent $534M on R&D in 2024—and need disciplined go/no-go decisions over the next 18 months to pick winners for Star-level investment.
- High growth, orphan-size markets; potential peak sales >$1B per program
High-risk, high-reward: Ionis' late-stage bets could unlock $1.5B–$8B markets by 2026–29
Question Marks: late/noncommercial assets (bepirovirsen, ION582, pelacarsen, siRNA/neurology pipeline) have high upside (addressable markets $1.5B–$8B; Lp(a) ~360M affected) but low share and high spend—Ionis R&D $534M–$894M (2024), success needs pivotal readouts/approvals by 2026–2029 to become Stars; failure risks write-downs.
| Asset | Stage | Market ($) | Key metric |
|---|---|---|---|
| bepirovirsen | Phase 3 | 6–8B (2030) | ~30% cure vs <1% SOC (Dec 2025) |
| ION582 | Phase 3 | 1.5–2.5B | 1/12,000–20,000 prevalence |
| pelacarsen | Phase 3 | 3–6B | ~360M elevated Lp(a) (2025) |
| siRNA & neurology | Early | 6.5B (siRNA 2025) | Ionis rev $894M; R&D >$200–534M (2024) |